Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Males or non-pregnant females from birth to \<18 years of age~2. Receiving standard of care antibiotic therapy for suspected or diagnosed Gram-negative infection or for peri-operative prophylaxis~3. Groups 1-4: Calculated creatinine clearance rate (CLCR) ≥ 80 ml/min/1.73m2 at baseline~4. Group 5: CLCR ≥ 50 ml/min/1.73m2 at baseline~5. Group 6: CLCR ≥ 20 ml/min/1.73m2 at baseline~Key Exclusion Criteria:~1. Known allergy/hypersensitivity to any β-lactam antibacterial~2. History of clinically significant renal, hepatic, or hemodynamic instability~3. Planned use of cardiopulmonary bypass or dialysis~4. Planned blood transfusion within 24 hours of study drug administration~5. Clinically significant abnormal laboratory test results not related to the underlying infection~6. Receipt of piperacillin/tazobactam within 24 hours of study drug administration~7. Likely to be at risk of hemodynamic disturbance following collection of the required PK blood samples

- Gender: ALL
- Minimum Age: 7 Days
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: ≥12 to <18 years TOL/TAZ 1000/500 mg FDC (Type: EXPERIMENTAL): Participants ≥12 to \<18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.
- Cohort 2: ≥7 to <12 years TOL/TAZ 18/9 mg/kg (Type: EXPERIMENTAL): Participants ≥7 to \<12 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1.
- Cohort 3: ≥2 to <7 years TOL/TAZ 18/9 or 30/15 mg/kg (Type: EXPERIMENTAL): Participants ≥2 to \<7 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
- Cohort 4: ≥3 months to <2 years TOL/TAZ 18/9 or 30/15 mg/kg (Type: EXPERIMENTAL): Participants ≥3 months to \<2 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
- Cohort 5: birth to <3 months TOL/TAZ 20/10 mg/kg (Type: EXPERIMENTAL): Participants from birth (\>32 weeks gestation, 7 days postnatal) to \<3 months of age received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 mg/kg was changed to TOL/TAZ 20/10.
- Cohort 6: birth to <3 months TOL/TAZ 12/6 or 20/10 mg/kg (Type: EXPERIMENTAL): Participants from birth (≤32 weeks gestation, 7 days postnatal) to \<3 months of age with creatinine clearance =20 - 49 mL/min/1.73 m\^2 received a single dose of TOL/TAZ 12/6 mg/kg as a 60-minute infusion on Day 1; participants with creatinine clearance ≥50 mL/min/1.73 m\^2 received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 was changed to TOL/TAZ 20/10 mg/kg for participants with creatinine clearance ≥50 mL/min/1.73 m\^2.

Based on this trial design, predict the completion outcome and termination type (if applicable).